Researchers at Florida International University (FIU) have discovered a new method to extend the lifespan and effectiveness of immune cells used in CAR-T therapy, a treatment that has transformed the fight against blood cancers like leukemia and lymphoma. The study, published as a preclinical breakthrough, addresses a critical limitation of CAR-T therapy: its inability to work against solid tumors and its tendency to become ineffective over time in blood cancers.
CAR-T therapy involves modifying a patient's own T cells to recognize and attack cancer cells. While it has been revolutionary for certain blood cancers, its efficacy wanes, and it has not been successful against solid tumors. The FIU researchers found a way to boost the lifespan and efficacy window of these immune cells, potentially expanding the therapy's impact. This discovery is particularly timely as numerous academic institutions and for-profit entities, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), are also advancing their own approaches in the field.
The implications of this research are significant. For patients with blood cancers, extending the effectiveness of CAR-T cells could mean longer remissions and reduced need for repeat treatments. For solid tumors, which account for the majority of cancers, this breakthrough could pave the way for CAR-T therapy to become a viable option, offering new hope to millions of patients worldwide. The oncology industry may see a shift in treatment paradigms, with CAR-T therapy potentially becoming a first-line treatment for a broader range of cancers.
The FIU findings are still in the preclinical stage, meaning they have been demonstrated in laboratory settings but not yet in human trials. However, the research provides a foundation for future clinical studies. If successful, it could lead to more durable and effective cancer treatments, reducing the burden on healthcare systems and improving patient outcomes.
This development also highlights the ongoing innovation in the biotechnology and life sciences sectors, where companies and academic institutions are racing to overcome the limitations of current immunotherapies. The news comes via BioMedWire, a specialized communications platform that covers the latest in biotech and biomedical sciences.
